Eficacia a 2 años de tocilizumab en pacientes con artritis reumatoide activa en la práctica clínica habitual

Notario Ferreira, Irene; Ferrer González, Miguel Ángel; Morales Garrido, Pilar; González Utrilla, Alfonso; García Sanchez, Antonio; Soto Pino, María José; Suero Rosario, Evelyn; Caro Hernández, Cristina; Añón Oñate, Isabel; Pérez Albaladejo, Lorena; Cáliz Cáliz, Rafael.
Reumatol. clín. (Barc.) ; 13(2): 78-84, mar.-abr. 2017. tab, graf
Artículo en Español | IBECS (España) | ID: ibc-161414

Documentos relacionados

  1. The pathogenesis of rheumatoid arthritis.
  2. [Effectiveness of tofacitinib combined with iguratimod in the treatment of difficult-to-treat moderate-to-severe rheumatoid arthritis].
  3. Sustained effectiveness and safety of subcutaneous tocilizumab over two years in the ARATA observational study.
  4. A national, multicenter, retrospective study evaluating retention rate and efficacy of tocilizumab treatment in patients with active rheumatoid arthritis who had an inadequate response to csDMARDs and/or TNF inhibitors.
  5. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis.
  6. Pre-treatment calprotectin (MRP8/14) provides no added value to testing CRP alone in terms of predicting response to TNF inhibitors in rheumatoid arthritis in a post hoc analysis.
  7. Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study.
  8. Influence of active versus placebo control on treatment responses in randomised controlled trials in rheumatoid arthritis.
  9. Development of prediction models to select older RA patients with comorbidities for treatment with chronic low-dose glucocorticoids.
  10. Adoption rates of recommended vaccines and influencing factors among patients with inflammatory arthritis: a patient survey.